AZ-1355

• Description:

  AZ-1355 is an orally active and effctive lipid-lowering agent. AZ-1355 inhibits platelet aggregation in vivo and elevates the prostaglandin I2/thromboxane A2 ratio in vitro[1].

• UNSPSC:

  12352005

• Target:

  Prostaglandin Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein

• Applications:

  Metabolism-sugar/lipid metabolism

• Field of Research:

  Endocrinology; Metabolic Disease

• Assay Protocol:

  https://www.medchemexpress.com/AZ-1355.html

• Purity:

  98.19

• Solubility:

  DMSO : 12.5 mg/mL (ultrasonic; warming; heat to 60°C)

• Smiles:

  O=C(C1=CC=C2OC3=C(OC)C=CC=C3CNC2=C1)OCC

• Molecular Formula:

  C17H17NO4

• Molecular Weight:

  299.32

• References & Citations:

  [1]Wada S, et al. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative. Atherosclerosis. 1981 Nov-Dec;40 (3-4) :263-71.

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  -20°C, 3 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  IP; TXA2/TP

• CAS Number:

  [75451-07-9]